MedTrace Logo

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

NCT04900818 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2026-03-05

No results posted yet for this study

Summary

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

TJ033721 (givastomig)

Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb)

DRUG

TJ033721 (givastomig) , nivolumab, chemotherapy

Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), nivolumab, chemotherapy

DRUG

TJ033721 (givastomig), chemotherapy

Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), chemotherapy

DRUG

TJ033721 (givastomig), durvalumab, chemotherapy

Tetravalent IgG(H)-scFv fusion-type of bi-specific antibody (BsAb), durvalumab, chemotherapy

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04900818 on ClinicalTrials.gov